Endothelial dysfunction accelerates AKI-to-CKD transition by promoting β-catenin activation in macrophages

Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD), resulting in long-term renal dysfunction. Although traditional risk factors such as hypertension, diabetes, and aging contribute to this transition, endothelial dysfunction has emerged as a central mediator. In a murine model of severe ischemia-reperfusion injury (IRI), we observed persistent fibrosis with sustained activation of β-catenin signaling, especially when there is an endothelial nitric oxide synthase (eNOS) deficiency. Impaired nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling exacerbated fibrosis by failing to suppress β-catenin activity. RNA sequencing at day 7 post-IRI revealed upregulation of genes related to macrophage differentiation. Flow cytometry demonstrated a biphasic macrophage response: CD11b⁺F4/80^low (M1-like) macrophages predominated on day 1, shifting to CD11b⁺F4/80^high (M2-like) macrophages by day 3, and then resolving by day 7. However, in eNOS knockout mice, M2 macrophages persisted beyond day 3, indicating sustained fibrogenic signaling. In vitro, NO-cGMP-PKG signaling inhibited IL-4-induced M2 polarization via β-catenin degradation, linking endothelial dysfunction to prolonged M2 activation. In vivo, macrophage depletion in eNOS-deficient mice significantly reduced interstitial fibrosis and improved renal function, confirming an important pathogenic role of M2 macrophages in AKI-to-CKD progression. Furthermore, pharmacological enhancement of cGMP signaling using a phosphodiesterase-5 (PDE5) inhibitor from day 7 post-IRI ameliorated fibrosis. Together, these findings suggest that endothelial dysfunction promotes a profibrotic macrophage milieu via Wnt/β-catenin activation and highlights the therapeutic potential of targeting NO-cGMP-β-catenin signaling to prevent CKD progression following AKI.NEW & NOTEWORTHY Our study provides novel insights into the mechanisms underlying the transition from acute kidney injury (AKI) to chronic kidney disease (CKD), with a focus on the role of endothelial nitric oxide synthase (eNOS). We believe our findings, particularly their potential implications for developing new therapeutic strategies to prevent CKD progression, will be of significant interest to your readership and could significantly improve patient care.